• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » non-small-cell lung cancer

Articles Tagged with ''non-small-cell lung cancer''

Lung cancer illustration
Cancer

STX-721 shows efficacy and selectivity in EGFR exon 20 mutant models

Nov. 9, 2022
Researchers from Scorpion Therapeutics Inc. presented preclinical data for the novel EGFR exon 20 mutant inhibitor STX-721, being developed for the treatment of non-small-cell lung cancer (NSCLC).
Read More
Cancer

Mirati Therapeutics discovers new KRAS G12C inhibitors for NSCLC

Nov. 8, 2022
Mirati Therapeutics Inc. has described GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer, in particular non-small-cell lung cancer (NSCLC).
Read More
Cancer

Navrogen enters CRADA with NCI to study anti-mesothelin ADC NAV-001 in clinic

Nov. 8, 2022
Navrogen Inc. has entered into a cooperative research and development agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI), part of the National Institutes of Health (NIH). Under this CRADA, Navrogen will sponsor the clinical investigation of the experimental antibody-drug conjugate (ADC) NAV-001, under supervision of the NCI.
Read More

CAB taxis to phase II lung win for Bioatla; AXL path greased?

Nov. 4, 2022
By Randy Osborne
Given Bioatla Inc.’s positive update from the study testing mecbotamab vedotin (BA-3011) in metastatic non-small-cell lung cancer sharpened investor thirst for more data by the end of this year, and Wall Street wanted to know how good the findings need to be in order to advance further.
Read More
Lung cancer illustration
Cancer

HER2 exon 20 mutation inhibitor shows promise for the treatment of NSCLC

Nov. 4, 2022
Approximately 1-3% of non-small-cell lung cancer (NSCLC) patients present HER2 exon 20 insertion (exon20ins) mutations.
Read More
Lung cancer illustration
Cancer

Preclinical characterization of BAY-2927088 in models of EGFR mutant NSCLC

Oct. 31, 2022
Researchers from Bayer AG presented the discovery of BAY-2927088, a new noncovalent tyrosine kinase inhibitor targeting EGFR exon 20 insertions and C797S resistance mutations in non-small-cell lung cancer (NSCLC).
Read More
Lung cancer illustration
Cancer

Prelude receives clearance for phase I study of SMARCA2 protein degrader PRT-3789 for solid tumors

Oct. 19, 2022
Prelude Therapeutics Inc. has received...
Read More
Cancer

Biomea Fusion allowed to begin clinical trial of BMF-219 in KRAS-mutant solid tumors

Oct. 17, 2022
Biomea Fusion Inc. has received IND clearance from the FDA to begin a phase I/Ib trial of BMF-219, a selective, covalent menin inhibitor in patients with unresectable, locally advanced, or metastatic non-small-cell lung cancer (NSCLC), colorectal cancer, or pancreatic ductal adenocarcinoma with an activating KRAS mutation.
Read More
Metastatic melanoma cells.
Immuno-oncology

Lyell receives IND clearance for phase I trial of TIL therapy LYL-845 for melanoma and solid tumors

Oct. 7, 2022
Lyell Immunopharma Inc. has received FDA clearance for its IND application to initiate a phase I trial for LYL-845, an investigational tumor-infiltrating lymphocyte (TIL) therapy enhanced with Lyell's Epi-R technology for patients with relapsed and/or refractory metastatic or locally advanced melanoma and other select solid tumors.
Read More
Cancer

New EGFR-mutant inhibitors discovered at Blueprint Medicines

Oct. 6, 2022
Blueprint Medicines Corp. has divulged new EGFR mutant inhibitors, particularly EGFR L858R mutant and EGFR del746-750 mutant, reported to be useful for the treatment of non-small-cell lung cancer.
Read More
Previous 1 2 … 26 27 28 29 30 31 32 33 34 … 41 42 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 29, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 29, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 29, 2025
  • Illustration of Microglia cells (red) in Alzheimer´s disease

    Two cancer drugs combined modify Alzheimer’s disease in mice

    BioWorld
    Current treatments for Alzheimer’s disease have limited effects. While they can slow cognitive decline or alleviate symptoms, they do not reverse this complex...
  • Opportunity compass with Chinese flag

    For big pharma, China is a shopper’s dream

    BioWorld
    Big pharma is increasingly shopping in China to fill its pipelines as it faces looming patent cliffs on major blockbusters coupled with growing pricing...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe